SEI Investments’s Cardiff Oncology CRDF Stock Holding History

SEI Investments’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-54,685	Closed	-$88.6K	–	3300
2026 Q1	$88.6K	Buy	+54,685	New	+$112K	﹤0.01%	3113
2020 Q4	–	Sell	-44,886	Closed	-$637K	–	2467
2020 Q3	$637K	Buy	+44,886	New	+$296K	﹤0.01%	1802
2018 Q3	–	Hold	0	–	–	–	2645
2018 Q2	–	Hold	0	–	–	–	3637

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SEI Investments's CRDF Position: Q2 2026 in Review

SEI Investments sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 54,685 shares — an estimated $88.6K sold.

SEI Investments first reported a position in CRDF in Q3 2020 and held it in 2 quarters. The position peaked at $637K in Q3 2020. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

SEI Investments reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
SEI Investments sold 54,685 Cardiff Oncology shares in Q2 2026, an estimated $88.6K.
SEI Investments first reported a position in Cardiff Oncology in Q3 2020 and held it in 2 quarters.
SEI Investments's Cardiff Oncology position peaked at $637K in Q3 2020.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.